Physician profile
Ashley Mueller
NPI 1295248961
$3,550.81
in general payments reported to CMS, 2019-2025
37 companies · $1,061 in 2025
The $1,061 reported for 2025 was more than what 87% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,255 · 2022: $396 · 2023: $230 · 2024: $609 · 2025: $1,061.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,900.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,899.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $698.21 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Pfizer INC. | $373.60 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $264.88 | 2021-2025 | Eliquis, Camzyos |
| Abbvie INC. | $241.36 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $226.70 | 2021-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $140.10 | 2021-2025 | Jardiance |
| Amgen INC. | $132.09 | 2024-2025 | Repatha, Otezla, Evenity |
| Lilly USA, LLC | $127.29 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Glaxosmithkline, LLC. | $123.04 | 2021-2025 | Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $106.46 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $105.98 | 2022 | |
| Itamar Medical INC | $98.83 | 2022 | |
| Dexcom, INC. | $87.93 | 2023-2025 | Dexcom G6 Transmitter |
| Bayer Healthcare Pharmaceuticals INC. | $80.27 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $78.42 | 2024-2025 | Keveyis |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Mueller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.